SAN DIEGO–(BUSINESS WIRE)–Progenity, a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced the appointment of Troy Seelye as Chief Information Officer (CIO). Mr. Seelye will help to strengthen Progenity’s technology and data strategy, leading the development of key products and services designed to transform the customer experience.
“Troy joins the Progenity executive team with a proven history of aligning technology to support core business objectives and maximizing efficiencies,” said Harry Stylli, PhD, CEO, chairman of the board, and co-founder of Progenity. “As we expand our diagnostic offerings and advance our diagnostic and therapeutic precision medicine platforms, his ability to execute innovative technology solutions will enable us to advance our pipeline toward the development of digital health solutions.”
Mr. Seelye brings more than 25 years of progressive leadership and IT experience in multiple high-growth global organizations, including Teradata, Illumina and Amgen. Most recently, Mr. Seelye led Teradata, a 40-year-old global provider of data warehousing and analytics solutions company, through a complex technology transformation driving corporate efficiencies and cost savings. Prior to his tenure with Teradata, Mr. Seelye led Global Information Services for Illumina, where he developed IT as a core function to the business, providing scalable technological solutions in support of rapid global growth. In addition, Mr. Seelye previously held various IT leadership roles throughout his 17 years with Amgen.
“I look forward to the opportunity to continue advancing Progenity’s technology infrastructure,” said Mr. Seelye, “With such a robust commercial pipeline, the importance of rapidly scaling our technology solutions is of key importance in using digital medicine to fill the gaps of patient care.”
Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies. For more information on how Progenity is helping clinicians and patients prepare for life, please visit www.progenity.com.